Derived from Atea’s nucleos(t)ide prodrug platform, bemnifosbuvir (AT-527) is an oral direct-acting antiviral, which is in Phase 2 development for the treatment of COVID-19. Its unique mechanism of action, with dual targets including chain termination (RdRp) and NiRAN inhibition, has the potential to create a high barrier to resistance with broad antiviral coverage to different variants of SARS-CoV-2.
Atea is a clinical stage biopharmaceutical company working to address unmet medical needs with innovative oral antiviral therapies.
Leveraging our platform, we have discovered and are rapidly advancing novel oral direct-acting antiviral drug candidates. Utilizing unique chemical modifications, these product candidates are designed to have the potential for enhanced antiviral activity and selectivity.
For the treatment of COVID-19, we need transformational solutions, and we believe that oral, safe, direct-acting antivirals can play an essential role worldwide. The value and global health impact of a direct-acting antiviral is to rapidly inhibit viral replication in the early phase of infection, which has the effect of reducing disease progression and curtailing the spread of infection.
While vaccines will play an important role in mitigating the COVID-19 pandemic, we will need treatment options to stay ahead of the virus.
Complementary medical intervention to vaccination
Oral administration has significant advantages:
Highly-conserved target has potential to enable antiviral activity in the presence of multiple variants
Antiviral activity against potential future coronaviruses beyond SARS-CoV-2 anticipated
Atea is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatments.
Copyright © 2020 By Atea Pharmaceuticals. All Rights Reserved. Privacy Policy | Terms of Use